Stocks to buy in 2025: Dr Lal PathLabs, Aurobindo Pharma among top 5 stocks which could rally 14-28% in 12 months

Brokerages such as CLSA, Macquarie, and Morgan Stanley have shared their ratings on prominent stocks like Dr. Lal Pathlabs, Aurobindo Pharma, Hindustan Unilever, HDFC Bank, and Polycab India. Recommendations indicate potential upsides ranging from 14% to 28% over the next 12 months, reflecting optimism about their growth prospects. Key target prices and ratings include upgrades and maintained outlooks.